Viatris Inc. (VTRS)
NASDAQ: VTRS · Real-Time Price · USD
9.60
-0.36 (-3.61%)
At close: Sep 15, 2025, 4:00 PM EDT
9.67
+0.07 (0.73%)
After-hours: Sep 15, 2025, 6:59 PM EDT
Viatris Revenue
Viatris had revenue of $3.58B in the quarter ending June 30, 2025, a decrease of -5.65%. This brings the company's revenue in the last twelve months to $14.12B, down -7.37% year-over-year. In the year 2024, Viatris had annual revenue of $14.74B, down -4.46%.
Revenue (ttm)
$14.12B
Revenue Growth
-7.37%
P/S Ratio
0.84
Revenue / Employee
$441,116
Employees
32,000
Market Cap
11.19B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 14.74B | -687.60M | -4.46% |
| Dec 31, 2023 | 15.43B | -835.80M | -5.14% |
| Dec 31, 2022 | 16.26B | -1.62B | -9.08% |
| Dec 31, 2021 | 17.89B | 5.94B | 49.73% |
| Dec 31, 2020 | 11.95B | 445.50M | 3.87% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
VTRS News
- 27 days ago - Viatris Appoints Andrew Enrietti as Chief Administrative and Transformation Officer - PRNewsWire
- 4 weeks ago - Dogs Of The S&P 500: Buy 19 Ideal "Safer" August Dividend Payers - Seeking Alpha
- 5 weeks ago - Viatris Announces Approval of First Generic Iron Sucrose Injection in the U.S. - PRNewsWire
- 5 weeks ago - Viatris Inc. (VTRS) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - Xanax-maker Viatris beats quarterly profit, revenue estimates; shares rise - Reuters
- 5 weeks ago - Viatris Reports Second Quarter 2025 Results and Reiterates 2025 Financial Guidance - PRNewsWire
- 5 weeks ago - Viatris Announces Quarterly Dividend - PRNewsWire
- 5 weeks ago - Viatris Announces Appointment of David Simmons to the Company's Board of Directors - PRNewsWire